Aspirin For MI Primary Prevention Indication Needs More Study, Panel Says
This article was originally published in The Tan Sheet
Executive Summary
A long-term randomized prospective trial of at least 15,000 patients would be needed to adequately support professional aspirin labeling on primary prevention of myocardial infarction, according to members of FDA's Cardiovascular & Renal Drugs Advisory committee